Physician profile
Richa Singh
NPI 1144575945
$6,643.03
in general payments reported to CMS, 2019-2025
43 companies · $740 in 2025
The $740 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $878 · 2020: $1,029 · 2021: $441 · 2022: $1,090 · 2023: $1,265 · 2024: $1,200 · 2025: $740.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,147 · Education: $58.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,146.76 |
| Education | $58.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,137.83 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $990.05 | 2019-2025 | Evenity, Repatha, Prolia |
| Lilly USA, LLC | $617.13 | 2019-2025 | Jardiance, Mounjaro, Trulicity |
| Bayer Healthcare Pharmaceuticals INC. | $446.42 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $433.17 | 2019-2025 | |
| Dexcom, INC. | $385.64 | 2019-2025 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $348.25 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Boehringer Ingelheim Pharmaceuticals, INC. | $328.71 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $250.32 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Astrazeneca Pharmaceuticals Lp | $204.70 | 2019-2022 | |
| Tandem Diabetes Care, INC. | $197.76 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Medtronic, INC. | $138.16 | 2021-2025 | Minimed 770g, Minimed 780g |
| Shire North American Group INC | $125.00 | 2019 | |
| Medtronic Minimed, INC. | $114.84 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $96.41 | 2022-2024 | Crysvita |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richa Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.